

**Listing of claims as amended**

1-16. (Cancelled)

17. (Withdrawn) A method of treating *diabetes mellitus* comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a bicyclic oligopeptide according to claim 1.

18. (New) A purified bicyclic oligopeptide comprised of (SEQ ID NO. 1):

[-----]

HN-Gly<sup>1</sup>-Leu-Pro-Trp-Gly-Cys<sup>6</sup>-Pro-Ser-Asp<sup>9</sup>-Ile-Pro-Gly-

|

-Trp-Asn-Thr-Pro-Trp-Ala-Cys<sup>19</sup>-COOR,

wherein

the amino group of Gly<sup>1</sup> is linked with the  $\beta$ -carboxylate group of Asp<sup>9</sup> via an amide group, and

the thiole groups of the cysteines Cys<sup>6</sup> und Cys<sup>19</sup> are linked via a disulfide bridge and R is a H atom or a methyl group;

or an ester thereof.

19. (New) A medicament comprised of a bicyclic oligopeptide according to claim 18.

20. A Pharmaceutical composition comprising a bicyclic oligopeptide according to claim 18 and a pharmacologically acceptable carrier.

21. A pharmaceutical composition according to claim 20 further comprised of an active ingredient selected from the group consisting of antidiabetic agents, lipid modulating agents, anti-obesity agents and cardiovascular agents.

22. A pharmaceutical composition according to claim 21, wherein the antidiabetic agent is selected from the group comprising biguanides, glucosidase inhibitors, PPARgamma modulators, dual PPARalpha/gamma agonists, RXR modulators, SGLT2 inhibitors, aP2 inhibitors, insulin sensitizers, GLP-1 or mimetics, DPPIV inhibitors, PTP-1B inhibitors, GSK-3 inhibitors and a metiglinide.

23. Pharmaceutical composition according to claim 22 wherein the antidiabetic agent is selected from the group consisting of metformin, glyburide, glibenclamide, glimepiride, glypiride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide, nateglinide, and exendin-4.